

Gaylord National Harbor, Washington, DC

September 30 – October 3, 2022

2022
Continuing
Education Book



2022 Program Committee



2022 Annual Scientific Meeting Program Committee

Co-Chairs

• 2022 Chair: David Lanfear, MD, MS

2022 Co-Chair: Rob DiDomenico, PharmD

• 2022 Co-Chair: Daniel Garry, MD, PhD

• 2022 Co-Chair: Cheryl Westlake, PhD, RN

Program Committee

- · Akshay Desai, MD
- · Zachary Cox, PharmD
- · Windy Alonso, PhD, RN
- Prateeti Khazanie, MD
- Amrut Ambardekar, MD
- Timothy Fendler, MD
- Ashley Hardin, MD
- · Line Kemeyou, MD
- Melissa Owen, RN, PhD
- Jo Ellen Rodgers, PharmD
- Emily Tsai, MD
- Leslie Cooper, MD
- Robert Malloy, NP
- · Nosheen Reza, MD
- Kelly Rogers, PharmD
- Esther Vorovich, MD
- Payman Zamani, MD





In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

The Heart Failure Society of America designates this live activity for a maximum of **45.75** AMA PRA Category 1 Credits™. Successful completion of this CME activity, which includes participation in the evaluation component and post-test with 75% passing score, enables the



participant to earn up to **9.25** MOC contact hours in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program.

Nurses

This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America. This activity is approved for a maximum **45.75** contact hours (which includes 11.75 hours of nursing pharmacology).

Pharmacology Hours for Nurses

For Nurses who require pharmacology hours for their certification or licensure renewal, this year the HFSA Annual meeting offers opportunities to accrue a maximum of 11.75 hours.

Saturday, October 1

1:45 PM | Credit Hours: 1.25

Session 3: Medical Therapy of Heart Failure with Reduced Ejection Fraction: New Guidelines and Evolving Clinical Practice

1:45 PM | Credit Hours: 1.25

Session 4: Dangerous Liaisons - Cardio-Oncology

3:15 PM | Credit Hours: 0.5

Session 7: Mission Impossible: Challenging Cardiogenic Shock Cases

3:15 PM | Credit Hours: 1.0

Session 8: Hypertrophic Cardiomyopathy: It's a New Dawn...And I'm Feeling Good

Sunday, October 2

9:45 AM | Credit Hours: 0.25

Session 14: Our Hearts Will Go On - What We Learned From COVID-19 and How We Move Forward

11:00 AM | Credit Hours: 0.5

Session 16: New Concepts and Controversies in Pulmonary Hypertension and Right Ventricular Failure

11:00 AM | Credit Hours: 0.5

Session 18: Myocardial Recovery: Patients with Improved and Dynamic EF

11:00 AM | Credit Hours: 0.25

Session 19: Let's Talk About Sex (Differences in Heart Failure)

2:15 PM | Credit Hours: 0.50 Session 22: *Controversies in HFpEF*

4:00 PM | Credit Hours: 1.25

Session 24: A Case-based Approach to Diagnosis and Management of Cardiac Amyloidosis

4:00 PM | Credit Hours: 0.5

Session 26: Oh the Place We'll Need to Go': Unmet Needs and Debates in Cardiogenic Shock

4:00 PM | Credit Hours: 0.5

Session 27: Implications of Comorbidities Across the HF Continuum

Monday, October 3

9:45 AM | Credit Hours: 1.00

Session 31: Emerging Concepts in Myocarditis – Immunity, Infection, Immunization

11:00 AM | Credit Hours: 0.50

Session 33: The Evolving Care of Patients with Durable LVADs in Advanced HF Care

11:00 AM | Credit Hours:1.00

Session 34: Clinical Conundrums

11:00 AM | Credit Hours: 1.00

Session 36: Great Debates



Pharmacists

The Heart Failure Society of America is an accredited provider of continuing pharmacy education (CPE). This event is accredited for up to 10.75 contact hours of knowledge-based CPE. ACPE Universal Activity Numbers (UAN): JA4008267-0000-22-008-L04-P (on-site/live virtual attendance only); JA4008267-0000-22-018-H04-P (on-demand/home study)



To earn credit for the live session, participants must complete the online evaluation for each presentation attended and submit their NABP ID and DOB (MMDD).

Once evaluations are completed, CPE will be uploaded to CPE monitor within 60 days of the close of the activity. Pharmacists wishing to claim credit for attending a session must fill out the session evaluation(s) and claim credits no later than 60 days of the activity completion date.

Attendees who participate on-site and via the virtual livestream will receive "L04" live credits; those watching on-demand will receive "H04" home study credits.

Any request for CPE after 60 days cannot be honored and credits will be forfeited.

Saturday, October 1

1:45 PM | Credit Hours: 1.25

Session 3: Medical Therapy of Heart Failure with Reduced Ejection Fraction: New Guidelines and Evolving Clinical Practice

1:45 PM | Credit Hours: 1.25

Session 4: Dangerous Liaisons - Cardio-Oncology

3:15 PM | Credit Hours: 1.25

Session 10: Nutrition and Obesity Management in Heart Failure

Sunday, October 2

11:00 AM | Credit Hours: 1.0

Session 17: Is the Hospital of the Future in Your Living Room? Acute Care Hospital at Home

11:00 AM | Credit Hours: 1.0

Session 18: Myocardial Recovery: Patients with Improved and Dynamic EF

2:15 PM | Credit Hours: 1.5 Session 22: Controversies in HFpEF 4:00 PM | Credit Hours: 1.25

Session 24: A Case-based Approach to Diagnosis and Management of Cardiac Amyloidosis

4:00 PM | Credit Hours: 1.25

Session 27: Implications of Comorbidities Across the HF Continuum

Monday, October 3
9:45 AM | Credit Hours: 1.25

Session 30: Signed, Sealed, and DELIVERed



Criteria for Successful Completion

Successful completion of this continuing education activity includes participation in the evaluation post course evaluation. For those sessions designated for MOC credits, participants must also achieve a passing score of 75% on the evaluation's post-test. See below for details on claiming credits while in the virtual meeting platform.

Claiming CE / MOC Credit

How to Claim CE Credit

To claim CE credit, learners must complete a session-specific evaluation. Click the "Claim CE" link in Virtual Meeting Platform. Participants will be prompted to click the evaluation link and be taken to the evaluation site. Once there, attendees will login with Last Name and Registration ID, locate session by Title Name, and complete form. Sessions that are approved for ABIM MOC credits will require a post-test and passing score. The link to the post-test will be found at the end of the evaluation form.

Onsite attendees will also have the option to visit the registration desk or the Continuing Education kiosks, located in the registration area, to access session evaluations.

All attendees, virtual and onsite, may also view a list of CE sessions and complete the corresponding post-session evaluation using this link: https://ceu.experientevent.com/HFS221

The deadline to claim CME, ABIM MOC, and Nursing credit is 11:59 PM EST on Friday, December 16, 2022. Pharmacy credits must be claimed within 60 days of activity completion. Any request for CPE after 60 days cannot be honored and credits will be forfeited.

How to Claim ABIM MOC Credit

Learners seeking to claim contact hours in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program will be asked to complete a session pre-test prior to the start of the session. At the conclusion of the session, the participant must complete a session evaluation and pass the post-test assessment with a 75% score.

Learners must provide the HFSA with their 6-digit ABIM number along with their Date of Birth (MMDD). The HFSA will report all successfully obtained MOC contact hours directly to the ABIM.

Pre-Test

Learners seeking to claim MOC or attending a satellite symposium are asked to complete a pre-test at the beginning of the activity. The "Pre-Test" for ABIM MOC sessions will be available in the Virtual Meeting Platform. Participants are asked to complete the pretest within 5 minutes of the start of the session.

Onsite Attendees

Pre-tests can be accessed in the mobile meeting app under the session page. To access a session pre-test in the mobile app, please download the "HFSA ASM 2022 Mobile App" in the mobile app store. Login to the mobile app with your meeting registration credentials and select your session under "Agenda." The pre-test will be available on the session page.





Virtual Attendees

Pre-tests will be found in the ASM 2022 virtual meeting platform under the session page.

To access a session pre-test in the virtual platform, please login to the ASM 2022 meeting platform (meeting.hfsa.org) with your meeting registration credentials. Next, select your session under "Agenda." The pre-test will be available on the right-hand side under the "Conferences I/O" tab.

The deadline to claim CE credit is 11:59 PM EST on Friday, December 16, 2022.

Pharmacy Credit: Additional Details

Learners seeking to claim continuing pharmacy education (CPE) credit hours must complete the online evaluation for each presentation attended and submit their NABP ID and DOB (MMDD). Once evaluations are completed, CPE will be uploaded to CPE monitor within 60 days of the close of the activity. Evaluations are available in the "Claim CE Credit" tab housed within the session player for a session offering CPE credits.

Pharmacists wishing to claim credit for attending a session must fill out the session evaluation(s) and claim credits no later than 60 days after the activity completion date.

Attendees who participate on-site and via the live virtual session will receive "L04" live credits; those watching on-demand will receive "H04" home study credits.

Any request for CPE **after** 60 days cannot be honored and credits will be forfeited.

Satellite Symposia Information

In support of improving patient care, the Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Satellite Symposia will each offer continuing education credit hours. Please refer to the satellite handout materials for exact hours of physician, nursing, and/or pharmacy credits where applicable.

Scientific Program Learning Objectives



Following this meeting, attendees will be able to:

- 1. Describe the epidemiology of HF and strategies for the prevention of HF.
- 2. Discuss the current scientific understanding of HF from the perspectives of cardiovascular physiology, neurohormones, molecular biology, and genetics.
- 3. Describe the findings of basic science research and recent clinical trials and describe their implications for current and future HF therapy.
- 4. Implement guideline-based therapy for HF, including pharmacologic agents and non-pharmacologic options such as diet, exercise, and implantable devices.
- 5. Manage comorbidities including hypertension, diabetes, depression, sleep apnea, and obesity.
- 6. Demonstrate awareness of psychosocial, economic, regulatory, and ethical issues in the treatment of patients with HF.
- 7. Explain the patient, provider and system-related factors that contribute to racial and ethnic health disparities.
- 8. Implement strategies for effective management of the patient with HF, incorporating the family, encouraging selfcare, and employing the team approach.
- 9. Outline strategies for transitioning patients from impatient to outpatient care and for reducing hospital readmissions.
- 10. Engage in performance measurement and site-based research.

Specific learning objectives for each of the scientific sessions and satellite symposia are listed in the session description in the virtual meeting platform.

Competencies Addressed

The 2022 scientific program contains content that addresses the following ABMS core competencies:

- Patient care
- Medical knowledge
- Interpersonal and communications skills
- Professionalism
- Systems-based practice
- Sessions also address the following ABIM specified competency areas in advanced heart failure and transplant cardiology:
- Epidemiology and risk factors

- Pathophysiology of heart failure
- Hemodynamics and hemodynamic monitoring
- Heart failure and normal ejection fraction
- Heart failure with renal dysfunction / cardiorenal syndrome
- Diagnostic tests and procedures
- Acute decompensation of chronic heart failure

- Subset of patients with heart failure, including women, the elderly, and different racial or ethnic groups
- Heart failure comorbidities
- Heart failure and pregnancy
- Cardiomyopathies
- Pharmacotherapy
- Implantable devices
- Heart transplant
- Mechanical circulator support
- End-of-Life Issues

Presentation Information



Audience Response System

Instructions for Attendees: For sessions utilizing the audience response system for audience polling and Q&A, please follow these instructions:

Onsite Attendees

A URL will be provided in the session room. Learners will be able to participate using their mobile device or laptop.

Virtual Attendees

A links will be provided on the Virtual Meeting Platform.

Meeting Content

The HFSA Annual Scientific Meeting 2022 provides a forum for the open exchange and discussion of research results and scientific advancements in the field of heart failure; however, HFSA makes no representation or warranty as to the truth, originality, or accuracy of the information presented. Nor are the views expressed by the individual speakers necessarily the view of HFSA. HFSA supports the Joint Accreditation policy on evidence-based content and requires faculty to adhere to these standards when preparing a presentation.

Presenter / Planner Disclosure Information

The Heart Failure Society of America (HFSA) is committed to fair and balanced educational content that is independent of industry influence. Participants are ensured objectivity and scientific rigor in all continuing education (CE) activities, free from the appearance of or actual conflicts of interest (COI).

It is the policy of the Heart Failure Society of America (HFSA) that all individuals who serve on a committee or in any position to influence the content of a certified CE activity must disclose all financial relationships with any ineligible companies that have occurred over the past 24 months. An ineligible company is defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; all financial relationships, regardless of the amount, with ineligible companies must be disclosed.

Faculty and Committee disclosure information is available on the HFSA Resource webpage in the virtual meeting platform. Speakers also have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the Joint Accreditation Standards for Integrity and Independence in Accredited Continuing Education.

Supporters



Supporters CE Satellite Symposium

The Heart Failure Society of America acknowledges the following for providing an unrestricted educational grant to support this year's Satellite Symposia.

American Regent, Inc.

AstraZeneca Pharmaceuticals

Boehringer Ingelheim Pharmaceuticals, Inc. /Lilly USA, LLC.

Bristol Myers Squibb

Cytokinetics Incorporated

Merck & Co., Inc.

Hands-On Workshops

The Heart Failure Society of America acknowledges the following for providing an unrestricted educational grant and/or in-kind donations to support this year's workshops.

Supported by unrestricted educational grants from:

Abbott

ABIOMED

Supported by in-kind education donations from:

Abbott

LivaNova

One Lambda, a part of Thermo Fisher Scientific, Inc.

Vyaire

Continuing Education Program



KEY: 🖻 MOC Session 💆 Pharmacy Credits 💆 Nursing Pharmacy Credits 🚔 Satellite Symposia 🐉 Scientific Session 🦃 Workshop

This is the CE Program only. For a complete listing of all meeting activities please refer to the Meeting Program.

Friday, September 30, 2022			Location
7:30PM - 9:00PM		Management of HFrEF: Will Novel Therapies Fit into Existing Treatment Paradigms? Supported through an unrestricted educational grant by Merck & Co., Inc.	National Harbor 2/3

Saturday, October 1, 2022			Location
8:00AM - 9:15AM	A E	Bridging the Gap Between Evidence and Clinical Practice: Improving Outcomes with SGLT2 Inhibitors in Patients with Heart Failure Supported through an unrestricted educational grant by AstraZeneca Pharmaceuticals	National Harbor 2/3
1:45PM - 2:45PM	\$	FDA Special Session: Background Medical Therapy for HF Clinical Trials	Potomac C
	\$	#ConstructivelyDisruptive at JCF	Potomac D
1:45PM - 3:00PM	* 2 =	Dangerous Liaisons - Cardio-Oncology	National Harbor 10/11
	\$	Many Roads Lead to Rome: Evolving Training Pathways for the Advanced Heart Failure and Critical Care Cardiologist	National Harbor 4/5
		Medical Therapy of Heart Failure with Reduced Ejection Fraction: New Guidelines and Evolving Clinical Practice	National Harbor 2/3
1:45PM - 3:15PM	ξ ^λ	Hands-On Workshop: Cardiogenic Shock (Limited Capacity)	Potomac 4/5
	\$	Women in Heart Failure: What are the Opportunities?	Potomac C
	\$ 2	Mission Impossible: Challenging Cardiogenic Shock Cases	Potomac D
3:15PM - 4:15PM	\$ 6 2	Hypertrophic Cardiomyopathy: It's a New DawnAnd I'm Feeling Good	National Harbor 2/3
	₩	New Device Based Therapies for Severe HF: Shunts etc.	National Harbor 10/11
	₩ =	Nutrition and Obesity Management in Heart Failure	National Harbor 4/5
7:00PM - 8:30PM	A E	Fine-Tuning the Management of Patients with Worsening Heart Failure with Reduced Ejection Fraction Supported through an unrestricted educational grant by Cytokinetics Incorporated	National Harbor 2/3
	889 A	Optimizing Heart Failure Outcomes with Intravenous Iron: Adaptive Approaches for Effective Diagnosis and Treatment of Iron Deficiency in HFrEF Supported through an unrestricted educational grant by American Regent, Inc.	National Harbor 10/11

Continuing Education Program



KEY: 📵 MOC Session 📮 Pharmacy Credits 💆 Nursing Pharmacy Credits 🚔 Satellite Symposia 🕸 Scientific Session 🥸 Workshop

Sunday, October 2,	2022		Location
6:45AM - 7:45AM		Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients with Hypertrophic Cardiomyopathy Supported through an unrestricted educational grant by Bristol Myers Squibb	National Harbor 2/3
8:00AM - 9:30AM		Sunday Plenary Session: Late Breaking Clinical Trials I	Potomac A/B
		Late Breaking Clinical Trials II Session	Potomac C
		Jay N. Cohn (JNC) New Investigator Award Competition	Potomac D
9:45AM - 10:45AM	₩	Novel Device Therapies in Heart Failure with Reduced Ejection Fraction	National Harbor 10/11
	8 2	Our Hearts Will Go On - What We Learned from COVID-19 and How We Move Forward	National Harbor 4/5
	* •	Heart Transplant Allocation in 2022	National Harbor 2/3
9:45AM - 11:15AM	ž.	Hands-On Workshop: CPET Basics (Limited Capacity)	Potomac 4/5
	\$	Nursing New Investigator Award Competition	Potomac D
	~~ =	Is the Hospital of the Future in Your Living Room? Acute Care Hospital at Home	National Harbor 2/3
11:00AM - 12:00PM	* 6 2 5	Myocardial Recovery: Patients with Improved and Dynamic EF	National Harbor 10/11
	2	Let's Talk About Sex (Differences in Heart Failure)	National Harbor 4/5
	® (New Concepts and Controversies in Pulmonary Hypertension and Right Ventricular Failure	Potomac C
2:15PM - 3:15PM	***	Multidisciplinary Heart Failure Clinics	Potomac D
	\$	Global Innovations in the Care of Patients with Heart Failure Mihai Gheorghaide Lecture	National Harbor 4/5
	\$	Leveraging Genetics for Heart Failure Therapy: Where Are We Headed?	National Harbor 2/3
2:15PM - 3:45PM	* 2 =	Controversies in HFpEF	National Harbor 10/11
	6	Referral for Advanced HF Care	Potomac C
押置	Š.	Hands-On Workshop: How to Manage and Monitor Patients with VADs: Alarms and PA Pressure Monitors (Limited Capacity)	Potomac 4/5
4:00PM - 5:15PM	\$ 2	"Oh the Places We'll Need to Go": Unmet Needs and Debates in Cardiogenic Shock	National Harbor 2/3
	***	Inherited Dilated Cardiomyopathies: Can We Rewrite the Stars?	Potomac D
	* 6 2 9	Implications of Comorbidities Across the HF Continuum	National Harbor 10/11
	\$ Ø ■	A Case-based Approach to Diagnosis and Management of Cardiac Amyloidosis	National Harbor 4/5

Continuing Education Program



KEY: 🖻 MOC Session 💆 Pharmacy Credits 💆 Nursing Pharmacy Credits 🚔 Satellite Symposia 🕸 Scientific Session 🥸 Workshop

4:00PM - 5:30PM		Excellence in Translational Science Thomas L. Force Lecture	Potomac C
5:30PM - 7:00PM		New Horizons in Treating Hypertrophic Cardiomyopathy: Practice Changing Molecules and Data Supported through an independent educational grant by Cytokinetics Incorporated	National Harbor 2/3
	A A	Expert Perspectives on the Evolving Treatment Paradigm in Heart Failure Management Supported through an independent educational grant by Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC	National Harbor 10/11

Monday, October 3	, 2022		Location
7:00AM - 7:45AM	***	Special DELIVERy: Emerging Insights Related to the DELIVER Trial	National Harbor 2/3
8:00AM - 9:30AM		Monday Plenary Session: Cardiac Xenotransplantation: Where We Are and Where We Are Going Featuring University of Maryland Heart Xenotransplant Team	Potomac A/B
9:45AM - 10:45AM	\$	Heart Failure Research Update: Conducting HF Trials in the U.S.	Potomac C
	\$	Debating Volume-based Versus Methods and Devices to Measure Congestion in Heart Failure	National Harbor 4/5
		Emerging Concepts in Myocarditis – Immunity, Infection, Immunization	National Harbor 10/11
	® •	Signed, Sealed, and DELIVERed	National Harbor 2/3
9:45AM - 11:00AM	žý.	Hands-On Workshop: Monitoring of Heart Transplant Rejection (Limited Capacity)	Potomac 4/5
11:00AM - 12:00PM	2	The Great Debates	National Harbor 4/5
	\$ 2	Clinical Conundrums	Potomac D
	\$ 2	The Evolving Care of Patients with Durable LVADs in Advanced HF Care	Potomac C
	* •	Health Equity in Heart Failure: Provider and Patient Perspectives	National Harbor 10/11

Exhibitor Floorplan + Directory at a Glance



- **715** Abbott
- 302 ABIOMED
- **104** Alnylam Pharmaceuticals, Inc.
- **129** American Association of Heart Failure Nurses
- **226** American College of Cardiology
- **127** American Heart Association
- **820** American Regent, Inc.
- **232** American Society of Echocardiography
- 203 AstraZeneca
- **821** AstraZeneca/Ionis Medical Affairs
- 224 BioVentrix, Inc
- **135** BMS Medical Affairs
- 234 Bodyport Inc
- **719** Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC
- 817 Boston Scientific
- 116 Bristol Myers Squibb
- 110 CardioSignal Inc
- 228 Cardiovascular Clinical Sciences
- 815 CareDx, Inc.
- 721 CMP Pharma
- 827 Cormeum
- **801** CVRx
- **501** Cytokinetics Incorporated
- 811 Daiichi Sankyo, Inc.
- **823** Daxor Corporation
- **920** Endotronix
- 316 GETINGE
- **227** Houston Shock Symposium
- 507 Impulse Dynamics
- 930 Innovaccer Inc.
- 233 Inova Heart and Vascular Institute
- 922 Invitae
- **229** Jant Pharmacal Corporation
- 326 Lantheus
- 928 Lexicon Pharmaceuticals, Inc.
- 314 Medtronic
- **301** Merck & Co., Inc.
- 822 Natera
- 315 Novartis Pharmaceuticals Corporation
- 207 Nuwellis, Inc.
- **910** 0M1
- **829** One Lambda, Inc., A Thermo Fisher Scientific Brand
- **729** Paragonix Technologies

- 701 Pfizer, Inc.
- **830** PhysioFlow/Manatec Biomedical
- **914** physlQ
- **826** Rhythm Science Inc
- **324** Sarfez Pharmaceuticals, Inc.
- **308** scPharmaceuticals
- **926** Sensible Medical
- 328 Ultromics
- 125 University of Maryland School of Pharmacy
- 916 V-Wave Inc.
- 225 VisCardia Inc.
- **727** Vyaire Medical
- **206** ZOLL
- **T1** BodiGuide Inc. Emerging Innovations Row 1
- **T2** General Prognostics (GPx) Emerging Innovations Row 2
- T3 Corlnnova, Inc. Emerging Innovations Row 3
- **T4** Renovacor Inc. Emerging Innovations Row 4

